To be fair, TD doesn’t typically present until patients have been on at least 3 months of dopamine blocking medication and this study was only 5 weeks. Based on moa, the development of TD seems unlikely, but only time will tell. Postmarketing experiences should be enlightening.
To be fair, TD doesn’t typically present until patients have been on at least 3 months of dopamine blocking medication and this study was only 5 weeks. Based on moa, the development of TD seems unlikely, but only time will tell. Postmarketing experiences should be enlightening.
There were hundreds of patients in extension label trials of the drug as submitted to FDA. Followed out to 52 weeks.